MwanzoAKUMS • NSE
add
Akums Drugs and Pharmaceuticals Ltd
Bei iliyotangulia
₹ 529.95
Bei za siku
₹ 510.00 - ₹ 543.00
Bei za mwaka
₹ 405.00 - ₹ 1,175.90
Thamani ya kampuni katika soko
81.22B INR
Wastani wa hisa zilizouzwa
elfu 438.94
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NSE
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (INR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 10.10B | -6.69% |
Matumizi ya uendeshaji wa biashara | 3.31B | 4.68% |
Mapato halisi | 651.82M | -66.35% |
Kiwango cha faida halisi | 6.45 | -63.95% |
Mapato kwa kila hisa | — | — |
EBITDA | 1.05B | -0.66% |
Asilimia ya kodi ya mapato | 27.17% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (INR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 7.95B | — |
Jumla ya mali | — | — |
Jumla ya dhima | — | — |
Jumla ya hisa | 28.47B | — |
hisa zilizosalia | 153.01M | — |
Uwiano wa bei na thamani | 2.79 | — |
Faida inayotokana na mali | — | — |
Faida inayotokana mtaji | 5.69% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (INR) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 651.82M | -66.35% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024.
Akums is India's largest Contract Development and Manufacturing Organization, driving pharmaceutical innovation and excellence in the Indian Pharmaceutical Market. From inception it has developed over 4,100 commercialized formulations across 60+ dosage forms, catering to key therapeutic areas such as cardio-diabetes, neurology, gynecology, nephrology, anti-infectives, respiratory, analgesics, and multi-vitamins. Our robust R&D capabilities have led to 220+ innovative formulations, supported by 22+ versatile platform technologies that enhance product development and differentiation. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
7,388
